Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Heineken NV
SWB:HNK1
|
NL |
|
Q
|
Quantgroup Holding Ltd
HKEX:2685
|
CN |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
US |
|
B
|
Bhagiradha Chemicals and Industries Ltd
NSE:BHAGCHEM
|
IN |
|
Giant Network Group Co Ltd
SZSE:002558
|
CN |
|
Kohinoor Foods Ltd
NSE:KOHINOOR
|
IN |
|
Dayu Water-saving Group Co Ltd
SZSE:300021
|
CN |
|
Mianyang Fulin Precision Co Ltd
SZSE:300432
|
CN |
|
J
|
JFB Construction Holdings
NASDAQ:JFB
|
US |
|
SOPerior Fertilizer Corp
OTC:POTRF
|
CA |
|
HanseYachts AG
XETRA:H9Y
|
DE |
|
Fastighets AB Balder
STO:BALD B
|
SE |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (0.2), the stock would be worth €0 (0% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | €0 |
0%
|
| 3-Year Average | 0.2 | €0 |
0%
|
| 5-Year Average | 0.2 | €0 |
0%
|
| Industry Average | 10.1 | €0.06 |
+5 784%
|
| Country Average | 14.4 | €0.08 |
+8 283%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Novan Inc
F:6LUA
|
1.3k EUR | 0.2 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 27.2 | 40.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 15 | 21.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.5 | 19.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 10 | 16.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 13 | 21.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 16.1 | 29.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 375.3 | -81.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 7.3 | 9.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 7.1 | 16.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
